home news forum careers events suppliers solutions markets expos directories catalogs resources advertise contacts
 
News Page

The news
and
beyond the news
Index of news sources
All Africa Asia/Pacific Europe Latin America Middle East North America
  Topics
  Species
Archives
News archive 1997-2008
 

Precision BioSciences and Cellectis SA announce cross-license and settlement agreement for gene editing technology - Enables broad commercialization of highly specific engineered meganuclease technology


Research Triangle Park, North Carolina, USA and Paris, France
January 30, 2014

Precision BioSciences, Inc. and Cellectis SA (Alternext: ALCLS), today announced that they have reached an agreement to settle patent litigation involving engineered I-CreI meganuclease technology. As part of the settlement, the companies will cross-license certain genome engineering patents and drop their on-going lawsuits and patent challenges. This agreement provides clear freedom to operate for both companies in the engineered I-CreI meganuclease genome engineering field.

Engineered meganucleases are one of the preferred genome engineering technologies for most high-value applications. Their small size and exquisite specificity make them safer and easier to deliver than alternative gene editing tools. In addition, current embodiments of the technology are versatile enough to edit any gene in a genome.

“We are pleased to have reached this agreement with our colleagues at Cellectis,” said Matthew Kane, Precision BioSciences’ CEO, “and are very much looking forward to focusing fully on the commercial development of highly needed products utilizing our Directed Nuclease Editor genome engineering technology.”

“This agreement with our colleagues at Precision Biosciences sets the value of innovation of a proven and effective genome engineering tool: meganucleases,” stated Dr. André Choulika, Chairman and CEO of Cellectis, “This natural technology has tremendous advantages and has now the full potential to be developed in a number important applications such as agricultural biology and bioproduction.”



More news from:
    . Elo Life Systems
    . Cellectis SA


Website: http://elolife.ag/

Published: January 30, 2014

The news item on this page is copyright by the organization where it originated
Fair use notice

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 

  Archive of the news section

 


Copyright @ 1992-2024 SeedQuest - All rights reserved